Bruker Corporation
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Bruker Corporation (Nasdaq: BRKR) develops, manufactures, and distributes high-performance scientific instruments and analytical and diagnostic solutions that enable customers to explore life and materials at molecular, cellular, and microscopic levels. The company offers a broad portfolio of products including nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) spectrometers; mass spectrometry systems; X-ray diffraction, scattering, and microscope analyzers; infrared, near-infrared, and Raman spectroscopy instruments; fluorescence and electron microscopy solutions; preclinical imaging systems; elemental analyzers; surface plasmon resonance systems; microbiology and clinical diagnostic tools such as ClinMASS and ClinDART kits; CBRNE detectors; semiconductor metrology equipment; and laboratory automation, data management, and test & measurement solutions. These products support applications in life science molecular research, pharmaceuticals, biotechnology, materials science, microscopy and nanoanalysis, industrial quality control, preclinical imaging, clinical phenomics and proteomics, and clinical microbiology. Founded in 1960 and headquartered in Billerica, Massachusetts, Bruker operates globally with over 11,000 employees across more than 90 locations on all continents, serving academic, governmental, pharmaceutical, biotechnology, and industrial customers. In April 2025, Bruker announced a majority investment in RECIPE Chemicals + Instruments GmbH, a Munich-based provider of clinical diagnostic assays, enhancing its small molecule diagnostics capabilities through integration of RECIPE's ClinMASS kits for EVOQ liquid chromatography triple-quadrupole mass spectrometers and upcoming high-throughput ClinDART kits for chromatography-free workflows on EVOQ-DART systems. Earlier, in 2024, the company acquired Dynamic Biosensors GmbH to strengthen its biosensor portfolio for molecular interaction analysis, complementing high-performance surface plasmon resonance systems like SPR #64 'Triceratops' for pharmaceutical and biotechnology drug discovery. Bruker also secured approximately $10 million in federally funded NMR system orders in October 2025 from institutions including the New York Structural Biology Center, University of Delaware, and Northwestern University, while initiating a major cost savings program targeting $100-120 million in annual reductions by fiscal 2026 amid market pressures.
Bruker Corporation (BRKR) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Bruker Signals Growth Pivot as Semiconductor and Overseas Orders Gain Steam
Bruker (BRKR) Up 37.1% Since Last Earnings Report: Can It Continue?
State Street SPDR S&P Pharmaceuticals vs First Trust NYSE Arca Biotech: Which Is the Better ETF For Your Portfolio?
Bruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio at ASM Microbe 2026
Bruker Launches new timsMRMS Mass Spectrometry Platform for Unique Ultra-Complex Mixture Applications in the Energy Industry
Bruker Launches new timsMRMS Mass Spectrometry Platform for Unique Ultra-Complex Mixture Applications in the Energy Industry
Bruker Announces Major Strides in 4D Proteomics Performance, Further Advances In Intact and Top-Down Functional Proteoform Analysis, and Innovations in Hybrid Qual/Quant 4D Metabolomics -- all to Enabl
Bruker Announces Major Strides in 4D Proteomics Performance, Further Advances In Intact and Top-Down Functional Proteoform Analysis, and Innovations in Hybrid Qual/Quant 4D Metabolomics – all to Enable Deeper Insights into Disease Biology
Champalimaud Foundation's Neuroscience and Oncology Research Benefits from 18 Tesla Ultra-High Field MRI
BRKR Stock Up Post Q1 Earnings & Revenue Beat, Margins Down
Bruker Corporation (BRKR) Q1 2026 Earnings Call Transcript
Bruker (BRKR) Surpasses Q1 Earnings and Revenue Estimates
Bruker Reports First Quarter 2026 Financial Results
Bruker Corp (BRKR) Shares Fall 5.4% -- What GF Score of 81 Tells Investors
Forget Neuralink: The Real Brain Tech Trade Has 10 Names You’ve Never Heard
Bruker Announces Date and Time of First Quarter 2026 Earnings Release and Webcast
A Look at Bruker Corp (BRKR) After 4.5% Gain -- GF Value $71.47 vs Price $40.70
Bruker Spatial Biology Showcases High Fidelity Spatial Data and Integrated Multi-platform Workflows for Unprecedented Multiomic Insights at AACR 2026
Bruker Expands Industry-Leading MALDI Biotyper® and IR Biotyper® Workflows for Microbial Identification and Outbreak Management